BR112013025969A2 - forma de dose unitária para administração oral - Google Patents
forma de dose unitária para administração oralInfo
- Publication number
- BR112013025969A2 BR112013025969A2 BR112013025969A BR112013025969A BR112013025969A2 BR 112013025969 A2 BR112013025969 A2 BR 112013025969A2 BR 112013025969 A BR112013025969 A BR 112013025969A BR 112013025969 A BR112013025969 A BR 112013025969A BR 112013025969 A2 BR112013025969 A2 BR 112013025969A2
- Authority
- BR
- Brazil
- Prior art keywords
- oral administration
- unit dose
- dose form
- hypoxia
- viable
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
forma de dose unitária para administração oral formulações e formas de dose unitária de th-302 e outros pró-fármacos ativados por hipóxia viáveis para administração oral são úteis para tratar câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161475844P | 2011-04-15 | 2011-04-15 | |
PCT/US2012/033671 WO2012142520A2 (en) | 2011-04-15 | 2012-04-13 | Unit dose form for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013025969A2 true BR112013025969A2 (pt) | 2016-12-20 |
Family
ID=47010017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013025969A BR112013025969A2 (pt) | 2011-04-15 | 2012-04-13 | forma de dose unitária para administração oral |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140072624A1 (pt) |
EP (1) | EP2696858A4 (pt) |
JP (1) | JP2014510795A (pt) |
KR (1) | KR20140045931A (pt) |
CN (1) | CN103458880A (pt) |
AU (1) | AU2012242514A1 (pt) |
BR (1) | BR112013025969A2 (pt) |
CA (1) | CA2832203A1 (pt) |
IL (1) | IL228709A0 (pt) |
MX (1) | MX2013011655A (pt) |
RU (1) | RU2013147744A (pt) |
WO (1) | WO2012142520A2 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1896040T3 (pl) | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals Inc | Proleki alkilatora fosforoamidowego |
WO2011119839A1 (en) | 2010-03-24 | 2011-09-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
US20150005262A1 (en) * | 2011-12-22 | 2015-01-01 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs and mtor inhibitors for treating cancer |
JP2015500885A (ja) | 2011-12-22 | 2015-01-08 | スレッショルド ファーマシューティカルズ,インコーポレイテッド | 癌を治療するためのchk1阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
WO2013126539A1 (en) * | 2012-02-21 | 2013-08-29 | Threshold Pharmaceuticals Inc. | Treatment of cancer |
WO2015013448A1 (en) | 2013-07-26 | 2015-01-29 | Threshold Pharmaceuticals, Inc. | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
CN108113976B (zh) * | 2018-02-27 | 2020-07-21 | 中国人民解放军总医院 | Th-302制剂、制备方法及其用途 |
CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
US11400052B2 (en) * | 2018-11-19 | 2022-08-02 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
CN109675039A (zh) * | 2018-12-21 | 2019-04-26 | 中国科学院长春应用化学研究所 | 药物组合、抗肿瘤的药物和应用 |
CN109700765A (zh) * | 2019-01-02 | 2019-05-03 | 无锡市妇幼保健院 | 一种靶向三阴性乳腺癌干细胞的光敏纳米脂质体 |
AU2020231916A1 (en) | 2019-03-01 | 2021-08-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
CN118076359A (zh) | 2021-08-27 | 2024-05-24 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2023198188A1 (zh) * | 2022-04-15 | 2023-10-19 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
WO2024179467A1 (zh) * | 2023-02-27 | 2024-09-06 | 深圳艾欣达伟医药科技有限公司 | 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5306727A (en) * | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
US8545881B2 (en) * | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
PL1896040T3 (pl) * | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals Inc | Proleki alkilatora fosforoamidowego |
ES2884044T3 (es) * | 2006-12-26 | 2021-12-10 | Immunogenesis Inc | Profármaco alquilante de fosforamidato para el tratamiento del cáncer |
ES2884674T3 (es) * | 2008-10-21 | 2021-12-10 | Immunogenesis Inc | Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed |
CA2803113A1 (en) * | 2010-06-28 | 2012-01-12 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
ES2877629T3 (es) * | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
-
2012
- 2012-04-13 EP EP12771554.8A patent/EP2696858A4/en not_active Withdrawn
- 2012-04-13 KR KR1020137028563A patent/KR20140045931A/ko not_active Application Discontinuation
- 2012-04-13 MX MX2013011655A patent/MX2013011655A/es not_active Application Discontinuation
- 2012-04-13 WO PCT/US2012/033671 patent/WO2012142520A2/en active Application Filing
- 2012-04-13 BR BR112013025969A patent/BR112013025969A2/pt not_active IP Right Cessation
- 2012-04-13 RU RU2013147744/15A patent/RU2013147744A/ru not_active Application Discontinuation
- 2012-04-13 JP JP2014505380A patent/JP2014510795A/ja active Pending
- 2012-04-13 CN CN2012800173194A patent/CN103458880A/zh active Pending
- 2012-04-13 CA CA2832203A patent/CA2832203A1/en not_active Abandoned
- 2012-04-13 AU AU2012242514A patent/AU2012242514A1/en not_active Abandoned
- 2012-04-13 US US14/110,819 patent/US20140072624A1/en not_active Abandoned
-
2013
- 2013-10-03 IL IL228709A patent/IL228709A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2013011655A (es) | 2013-11-01 |
CA2832203A1 (en) | 2012-10-18 |
RU2013147744A (ru) | 2015-05-20 |
WO2012142520A3 (en) | 2013-01-03 |
JP2014510795A (ja) | 2014-05-01 |
KR20140045931A (ko) | 2014-04-17 |
CN103458880A (zh) | 2013-12-18 |
AU2012242514A1 (en) | 2013-10-24 |
EP2696858A4 (en) | 2014-09-03 |
US20140072624A1 (en) | 2014-03-13 |
EP2696858A2 (en) | 2014-02-19 |
WO2012142520A2 (en) | 2012-10-18 |
IL228709A0 (en) | 2013-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013025969A2 (pt) | forma de dose unitária para administração oral | |
CY1124499T1 (el) | Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα | |
CY1120730T1 (el) | Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1 | |
UY34542A (es) | ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?. | |
CY1120204T1 (el) | Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο | |
CU20130094A7 (es) | Moduladores de la vía del complemento | |
PH12016501790A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
CR20150326A (es) | Inhibidores de autotaxina | |
MX2015011897A (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
EA201390804A1 (ru) | Лекарственная форма лакозамида для приема один раз в сутки | |
CR20200479A (es) | COMPUESTOS TERAPÉUTICAMENTE ACTIVOS Y SUS MÉTODOS DE USO (Divisional 2016-0069) | |
GB201118656D0 (en) | New compounds | |
BR112013025415A2 (pt) | métodos para aumentar eficácia de terapia de câncer de folr1 | |
PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
UY34078A (es) | Composiciones farmacéuticas y métodos para tratar el cáncer | |
UY34178A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos. | |
MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
CO7121334A2 (es) | Formulaciones vesiculares | |
CY1120545T1 (el) | Συνθεση για τη θεραπεια της διαταραχης μειωμενης σεξουαλικης επιθυμιας | |
BR112015009839A2 (pt) | composição farmacêutica de tapentadol para administração parenteral | |
MX348147B (es) | Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer. | |
AR085105A1 (es) | Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7) | |
UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |